Samuel Ng obtained his LLB (1999) and PCLL (2000) from the University of Hong Kong. His practice focuses on a diverse range of corporate finance and securities matters, including securities offerings, M&A, corporate restructurings, private equity investments and other corporate transactions in Hong Kong and China, as well as regulatory and compliance work.
Mr. Ng has worked in the Hong Kong Stock Exchange where he approved various Main Board IPOs and oversaw the ongoing compliance and monitoring for Main Board listed issuers.
Mr. Ng was recommended by The Legal 500 Asia-Pacific 2020-2021 for Corporate (including M&A) and Equity Capital Markets in Hong Kong, named by IFLR 1000 as Notable Practitioner for Equity Capital Markets in Hong Kong, 2021-2022, recommended by The Legal 500 Asia-Pacific 2019 for Corporate (including M&A) in Hong Kong, recommended by The Legal 500 Asia-Pacific 2018 for Equity Capital Markets in Hong Kong, and named to Asian Legal Business 2015 “40 Under 40” list of Asia’s brightest legal minds under the age of 40.
Mr. Ng speaks fluent English, Cantonese, and Mandarin.
Assisted Sino-Synergy Hydrogen Energy Technology (Jiaxing) Co., Ltd., a leading technology-based hydrogen fuel cell company in the PRC focusing on research, development, production and sales of hydrogen fuel cell stacks and hydrogen fuel cell systems, in its HK$1,698 million IPO on the Hong Kong Stock Exchange (represented Huatai Financial Holdings (Hong Kong) Limited as the sole sponsor).
Represented Mega Genomics Limited, the largest consumer genetic testing platform in China in terms of the cumulative number of tests administered, on its US$27.56 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange. China Securities International acted as the sole sponsor for this transaction.
Represented SinoMab BioScience Limited, a biopharmaceutical company dedicated to R&D of therapeutics for the treatment of immunological diseases, in its US$176.5 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange as a Chapter 18A biotech company. CICC and Orient Capital acted as the joint sponsors.
Represented Fosun Tourism Group, one of the world’s leading leisure-focused integrated tourism groups, in its spin-off from Fosun International and US$428 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange. J.P. Morgan, CLSA and Citigroup acted as the joint sponsors. Also assisted Fosun International in its PN15 spin-off application. This transaction was commended as a “Most Innovative Deal 2019” by Financial Times Asia-Pacific Innovative Lawyers Report.
Assisted Tsit Wing International Holdings Limited, a leading integrated B2B coffee and black tea solution provider in Hong Kong, Macau, and China, in its US$68 million IPO on the Hong Kong Stock Exchange (advised BOCI and BOSC International as the joint sponsors).
Represented Shanghai Dazhong Public Utilities (Group) Co., Ltd., an A-share listed company on the Shanghai Stock Exchange and a leading public utility service provider in Shanghai, in its US$218 million offering of H-shares on the Hong Kong Stock Exchange. CICC and Haitong International acted as the joint sponsors.
Assisted Luzhou Xinglu Water (Group) Company Limited, a leading integrated water provider in Sichuan Province, in its US$63 million IPO on the Hong Kong Stock Exchange (advised BOCOM International as the sole sponsor).
Assisted Dynagreen Environmental Protection Group Co Ltd., a leading waste-to-energy company, in PRC focusing on municipal solid waste treatment in its US$142 million H-share IPO and listing of shares on the Hong Kong Stock Exchange (advised CITIC Securities as sole sponsor and underwriter and CLSA as sole global coordinator).